Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

But so far, most researchers are reassured as are regulators in the UK, United States and Europe.”Prof Sattar and Dr Cork have unpacked the side effects to be aware of:BlindnessStomach issues‘Ozempic ...

In Garg’s own pilot study, a retrospective chart review of ... 150 patients with T1D, weight loss was twice as great with tirzepatide (21.4%) than with semaglutide (9.1%). In a recent double ...

There’s a lot to remember when taking a GLP-1 medication. Here are 5 ways to use the Lose It! app to help optimize your ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

1 Multiple trials, including hundreds of obese/overweight women in the menopausal/postmenopausal age group, reflect weight loss of at least 5% with three months of semaglutide treatment.

Analysis is ongoing to compare differences in weight loss, lean mass, and fat mass reduction between those using tirzepatide and those using semaglutide. The researchers explained that their six ...